Edition:
United Kingdom

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

80.70EUR
23 May 2018
Change (% chg)

€-1.20 (-1.47%)
Prev Close
€81.90
Open
€82.05
Day's High
€82.05
Day's Low
€79.50
Volume
120,090
Avg. Vol
93,571
52-wk High
€82.70
52-wk Low
€65.05

Select another date:

Thu, Apr 5 2018

BRIEF-Diasorin Receives FDA Clearance For Liaison Brahms Percent II Gen Assay For Sepsis

* RECEIVES FDA CLEARANCE FOR LIAISON BRAHMS PERCENT II GEN ASSAY TO DETECT SEVERE BACTERIAL INFECTIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin Earns FDA Clearance Extending Sample Claims For HSV 1 & 2 Test

* EARNS FDA CLEARANCE EXTENDING SAMPLE CLAIMS FOR SIMPLEXA HSV 1 & 2 DIRECT MOLECULAR TEST

BRIEF-DiaSorin FY Net Profit Up At EUR 139.9 Mln

* FY REVENUE EUR 637.5 MILLION VERSUS EUR 569.3 MILLION YEAR AGO

BRIEF-DiaSorin Sees Tax Benefit In 2015-2017 Of 16-18 Mln Euros From Patent Box

* SIGNS AGREEMENT WITH TAX OFFICE REGARDING PATENT BOX TAX REGIME

BRIEF-Qiagen, DiaSorin partner in automated tuberculosis detection

* SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​

BRIEF-Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis

* ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS

BRIEF-Diasorin Receives CE Mark For A New Bordetella Molecular Diagnostic Test

* RECEIVES CE MARK FOR A NEW BORDETELLA MOLECULAR DIAGNOSTIC TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: